Pharmacoeconomic analysis of dapagliflozin in patients with chronic kidney disease and type 2 diabetes in the Russian Federation
Background. The economic costs associated with chronic kidney disease (CKD) are a significant burden on the health care system. The use of dapagliflozin is a breakthrough strategy in the management of patients with CKD and type 2 diabetes mellitus (T2DM) to slow the progression of the disease and re...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
LLC "MEDIAFORMAT"
2024-02-01
|
| Rangatū: | Клинический разбор в общей медицине |
| Ngā marau: | |
| Urunga tuihono: | https://klin-razbor.ru/en/archive/2022/vol-3-2-2022/pharmacoeconomic-analysis-of-dapagliflozin-in-patients-with-chronic-kidney-disease-and-type-2-diabet_6224/?element |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|